Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

526
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
526
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

441
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
441
Bipolar Disorder01:30

Bipolar Disorder

591
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
591
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

776
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
776
Drug Therapy01:28

Drug Therapy

232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
232
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

770
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
770

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Friend and Confidant Thresholds: Social Network Size as a Mediator Between Marital Status and Major Depressive Disorder.

Depression and anxiety·2026
Same author

Effects of a nurse-led navigation program for first-time pregnant Korean women on maternal anxiety and childbirth confidence: a quasi-experimental study.

Women's health nursing (Seoul, Korea)·2026
Same author

Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis.

Minerva gastroenterology·2026
Same author

Signal Detection and Machine Learning-Based Prediction of Cytokine Release Syndrome in B-Cell Maturation Antigen-Targeting Immunotherapies Using FAERS Data.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Clinical Efficacy and Safety Profile of Bimekizumab in Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Endocrine, metabolic & immune disorders drug targets·2026

Related Experiment Video

Updated: Jan 8, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

236

Managing Bipolar Disorder With Aripiprazole Once Monthly: From Symptom Stabilization to Functional Recovery.

Hye Ryun Yang1, Sra Jung2, Jiwan Moon1

  • 1Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Psychiatry Investigation
|December 17, 2025
PubMed
Summary

Monthly aripiprazole injections significantly improved functioning and reduced symptoms in South Korean bipolar disorder patients over one year. This long-acting injectable treatment also decreased the need for other mood stabilizers and antipsychotics.

Keywords:
Aripiprazole once monthlyBipolar disorderLong-acting injectable

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.2K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:11

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

223

Related Experiment Videos

Last Updated: Jan 8, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
10:54

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

236
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.2K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:11

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

223

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Research

Background:

  • Medication adherence is critical for managing bipolar disorder long-term.
  • Aripiprazole long-acting injectable (LAI) administered monthly is increasingly used to improve adherence and manage bipolar disorder.
  • Limited research exists on aripiprazole LAI's effectiveness in South Korean bipolar disorder populations.

Purpose of the Study:

  • To evaluate the efficacy of once-monthly aripiprazole in South Korean patients with bipolar disorder.
  • To assess the impact of aripiprazole LAI on functional outcomes and symptom severity.
  • To analyze changes in concomitant medication use during aripiprazole LAI treatment.

Main Methods:

  • A non-interventional, retrospective study analyzing medical records of bipolar disorder patients treated with aripiprazole LAI.
  • Data collection occurred at 1, 3, 6, 9, and 12 months post-initiation.
  • Standardized scales (GAF, CGI-BP-S, YMRS, K-MADRS, HAM-A) measured functional and symptom changes; medication dosages were also recorded.

Main Results:

  • Significant improvements observed in Global Assessment of Functioning (GAF) scores (+25.7%, p=0.001) over 12 months.
  • Marked reductions in symptom severity scores including CGI-BP-S (-24.4%), YMRS (-81.2%), K-MADRS (-36.2%), and HAM-A (-36.1%) (all p<0.003).
  • A significant decrease in the total pill count and dosages of concurrent mood stabilizers and antipsychotics was noted.

Conclusions:

  • Once-monthly aripiprazole treatment demonstrated significant improvements in functional outcomes and mood symptoms for bipolar disorder patients.
  • Aripiprazole LAI facilitated a reduction in the need for other psychiatric medications.
  • The findings underscore the value of long-acting injectable antipsychotics in enhancing overall well-being and treatment adherence in bipolar disorder management.